AI assistant
Kalaris Therapeutics, Inc. — Director's Dealing 2022
Jul 6, 2022
34070_dirs_2022-07-06_64f37a19-c1e2-445b-98a3-687976729ada.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Allovir, Inc. (ALVR)
CIK: 0001754068
Period of Report: 2022-07-01
Reporting Person: Brainard Diana (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-07-01 | Common Stock | A | 48125 | $0.00 | Acquired | 542112 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-07-01 | Stock Option (Right to Buy) | $4.13 | A | 89375 | Acquired | 2032-07-01 | Common Stock (89375) | Direct |
Footnotes
F1: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on July 1, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.
F2: Includes 1,822 shares acquired under the Allovir, Inc. 2020 Employee Stock Purchase Plan on June 30, 2022.
F3: 25% of this option shall vest and become exercisable on July 1, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.